Donald Trump just created a big headache for Big Pharma.

Shares of pharmaceutical stocks fizzled on Wednesday, falling as much as 5 percent, after tough talk by the president-elect on pricing.

Uncle Sam doesn’t drive a hard bargain when buying drugs, Trump said.

Without a tough US negotiating, drugmakers are “getting away with murder,” Trump said. “Pharma has a lot of lobbyists and a lot of power, and there is very little bidding. We’re the largest buyer of drugs in the world and yet we don’t bid properly, and we’re going to save billions of dollars.”

“We have to get our drug industry back,” he added. “They don’t make them here for a large extent.”

Trump, who takes office in eight days, suggested during his Wednesday press conference that there should be price controls.

Trump’s comments were echoed by Sen. Bernie Sanders (I-Vt.), who took to Twitter to say that “Trump is right” to take on Big Pharma.

Trump comments were still echoing off the wall of the Trump Tower room where the presser was held when drug company shares started a sell-off.

Pfizer lost nearly $5 billion in value in just 18 minutes, falling 2.4 percent, to $32.57 at 11:40 a.m.

The company’s shares closed at $32.83, down 1.8 percent.

Bristol-Myers Squibb, maker of blood-thinning drug Coumadin, was one of the companies hit the hardest. It fell 5.3 percent on the day, to $56.80.

An iShares exchange-traded fund of major pharma companies fell as much as 3.3 percent, to $142.40, after Trump’s remarks, though it ended slightly up, to $144.08.

Drug companies have been a popular target for politicians in the last few years.

Mylan faced major public pressure to release a generic version of the EpiPen after hiking the price of the life-saving auto-injector by 400 percent.

Martin Shkreli also hiked the price of cancer drug Daraprim to $750 a pill from $13.50, earning him the nick-name “Pharma-douche.”